Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to studying neoadjuvant IBI308, bevacizumab, plus pemetrexed and
carboplatin followed by surgery to see how well it works in treating patients with
unresectable stage III non-small cell lung cancer.